Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
12,214
archived clinical trials in
Women's Studies

Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Status: Enrolling
Updated:  2/19/2016
EndoCeutics site # 50
mi
from
Neptune, NJ
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Status: Enrolling
Updated: 2/19/2016
EndoCeutics site # 50
mi
from
Neptune, NJ
Click here to add this to my saved trials
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Status: Enrolling
Updated:  2/19/2016
EndoCeutics site # 33
mi
from
Beachwood, OH
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Status: Enrolling
Updated: 2/19/2016
EndoCeutics site # 33
mi
from
Beachwood, OH
Click here to add this to my saved trials
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Status: Enrolling
Updated:  2/19/2016
EndoCeutics site # 05
mi
from
Cleveland, OH
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Status: Enrolling
Updated: 2/19/2016
EndoCeutics site # 05
mi
from
Cleveland, OH
Click here to add this to my saved trials
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Status: Enrolling
Updated:  2/19/2016
EndoCeutics site # 15
mi
from
Columbus, OH
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Status: Enrolling
Updated: 2/19/2016
EndoCeutics site # 15
mi
from
Columbus, OH
Click here to add this to my saved trials
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Status: Enrolling
Updated:  2/19/2016
EndoCeutics site # 62
mi
from
Providence, RI
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Status: Enrolling
Updated: 2/19/2016
EndoCeutics site # 62
mi
from
Providence, RI
Click here to add this to my saved trials
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Status: Enrolling
Updated:  2/19/2016
EndoCeutics site # 64
mi
from
Jackson, TN
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Status: Enrolling
Updated: 2/19/2016
EndoCeutics site # 64
mi
from
Jackson, TN
Click here to add this to my saved trials
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Status: Enrolling
Updated:  2/19/2016
EndoCeutics site # 63
mi
from
Memphis, TN
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Status: Enrolling
Updated: 2/19/2016
EndoCeutics site # 63
mi
from
Memphis, TN
Click here to add this to my saved trials
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Status: Enrolling
Updated:  2/19/2016
EndoCeutics site # 53
mi
from
San Antonio, TX
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Status: Enrolling
Updated: 2/19/2016
EndoCeutics site # 53
mi
from
San Antonio, TX
Click here to add this to my saved trials
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Status: Enrolling
Updated:  2/19/2016
EndoCeutics site # 51
mi
from
Sandy, UT
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Status: Enrolling
Updated: 2/19/2016
EndoCeutics site # 51
mi
from
Sandy, UT
Click here to add this to my saved trials
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Status: Enrolling
Updated:  2/19/2016
EndoCeutics site # 09
mi
from
West Jordan, UT
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Status: Enrolling
Updated: 2/19/2016
EndoCeutics site # 09
mi
from
West Jordan, UT
Click here to add this to my saved trials
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Status: Enrolling
Updated:  2/19/2016
EndoCeutics site # 03
mi
from
Norfolk, VA
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Status: Enrolling
Updated: 2/19/2016
EndoCeutics site # 03
mi
from
Norfolk, VA
Click here to add this to my saved trials
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Status: Enrolling
Updated:  2/19/2016
EndoCeutics site # 13
mi
from
Calgary,
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Status: Enrolling
Updated: 2/19/2016
EndoCeutics site # 13
mi
from
Calgary,
Click here to add this to my saved trials
Topical DHEA Against Vaginal Atrophy
Topical DHEA Against Vaginal Atrophy (3-Month Placebo-Controlled Double-Blind Randomized Phase III Study)
Status: Enrolling
Updated:  2/19/2016
EndoCeutics site # 05
mi
from
Cleveland, OH
Topical DHEA Against Vaginal Atrophy
Topical DHEA Against Vaginal Atrophy (3-Month Placebo-Controlled Double-Blind Randomized Phase III Study)
Status: Enrolling
Updated: 2/19/2016
EndoCeutics site # 05
mi
from
Cleveland, OH
Click here to add this to my saved trials
Topical DHEA Against Vaginal Atrophy
Topical DHEA Against Vaginal Atrophy (3-Month Placebo-Controlled Double-Blind Randomized Phase III Study)
Status: Enrolling
Updated:  2/19/2016
EndoCeutics site # 03
mi
from
Norfolk, VA
Topical DHEA Against Vaginal Atrophy
Topical DHEA Against Vaginal Atrophy (3-Month Placebo-Controlled Double-Blind Randomized Phase III Study)
Status: Enrolling
Updated: 2/19/2016
EndoCeutics site # 03
mi
from
Norfolk, VA
Click here to add this to my saved trials
Topical DHEA Against Vaginal Atrophy
Topical DHEA Against Vaginal Atrophy (3-Month Placebo-Controlled Double-Blind Randomized Phase III Study)
Status: Enrolling
Updated:  2/19/2016
EndoCeutics site # 10
mi
from
Montreal,
Topical DHEA Against Vaginal Atrophy
Topical DHEA Against Vaginal Atrophy (3-Month Placebo-Controlled Double-Blind Randomized Phase III Study)
Status: Enrolling
Updated: 2/19/2016
EndoCeutics site # 10
mi
from
Montreal,
Click here to add this to my saved trials
A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia
A Pilot Translational Study of Tetra-O-Methyl Nordihydroguaiaretic Acid (EM-1421) for the Treatment of Cervical Intraepithelial Neoplasia Induced by Human Papilloma Virus
Status: Enrolling
Updated:  2/20/2016
University of Maryland, Dept. of Family Medicine
mi
from
Baltimore, MD
A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia
A Pilot Translational Study of Tetra-O-Methyl Nordihydroguaiaretic Acid (EM-1421) for the Treatment of Cervical Intraepithelial Neoplasia Induced by Human Papilloma Virus
Status: Enrolling
Updated: 2/20/2016
University of Maryland, Dept. of Family Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated:  2/22/2016
Huntington Memorial Hospital
mi
from
Pasadena, CA
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated: 2/22/2016
Huntington Memorial Hospital
mi
from
Pasadena, CA
Click here to add this to my saved trials
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated:  2/22/2016
Presbyterian/St Luke's Hospital
mi
from
Denver, CO
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated: 2/22/2016
Presbyterian/St Luke's Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated:  2/22/2016
OSF St. Francis Medical Center-Children's Hospital of Illinois
mi
from
Peoria, IL
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated: 2/22/2016
OSF St. Francis Medical Center-Children's Hospital of Illinois
mi
from
Peoria, IL
Click here to add this to my saved trials
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated:  2/22/2016
Palmetto Health Richland Hospital
mi
from
Columbia, SC
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated: 2/22/2016
Palmetto Health Richland Hospital
mi
from
Columbia, SC
Click here to add this to my saved trials
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated:  2/22/2016
Palmetto Health Baptist Hospital
mi
from
Columbia, SC
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated: 2/22/2016
Palmetto Health Baptist Hospital
mi
from
Columbia, SC
Click here to add this to my saved trials
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated:  2/22/2016
Driscoll Children's Hospital
mi
from
Corpus Christi, TX
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated: 2/22/2016
Driscoll Children's Hospital
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated:  2/22/2016
Baylor University Medical Center
mi
from
Dallas, TX
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated: 2/22/2016
Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated:  2/22/2016
Las Palmas Medical Center
mi
from
El Paso, TX
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated: 2/22/2016
Las Palmas Medical Center
mi
from
El Paso, TX
Click here to add this to my saved trials
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated:  2/22/2016
R.E. Thomason Hospital
mi
from
El Paso, TX
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated: 2/22/2016
R.E. Thomason Hospital
mi
from
El Paso, TX
Click here to add this to my saved trials
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated:  2/22/2016
Del Sol Medical Center
mi
from
El Paso, TX
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated: 2/22/2016
Del Sol Medical Center
mi
from
El Paso, TX
Click here to add this to my saved trials
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated:  2/22/2016
Cook Children's Medical Center
mi
from
Fort Worth, TX
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated: 2/22/2016
Cook Children's Medical Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated:  2/22/2016
St. Joseph Medical Center
mi
from
Houston, TX
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated: 2/22/2016
St. Joseph Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated:  2/22/2016
Children's Memorial Hermann Hospital
mi
from
Houston, TX
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated: 2/22/2016
Children's Memorial Hermann Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated:  2/22/2016
Memorial Hermann Southwest Hospital
mi
from
Houston, TX
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated: 2/22/2016
Memorial Hermann Southwest Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated:  2/22/2016
Clear Lake Regional Medical Center
mi
from
Webster, TX
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status: Enrolling
Updated: 2/22/2016
Clear Lake Regional Medical Center
mi
from
Webster, TX
Click here to add this to my saved trials
Estimating the Global Need for Palliative Care for Children
Estimating the Global Need for Palliative Care for Children: A Cross Sectional Analysis
Status: Enrolling
Updated:  2/22/2016
International Children's Palliative Care Network
mi
from
Fairfax Station, VA
Estimating the Global Need for Palliative Care for Children
Estimating the Global Need for Palliative Care for Children: A Cross Sectional Analysis
Status: Enrolling
Updated: 2/22/2016
International Children's Palliative Care Network
mi
from
Fairfax Station, VA
Click here to add this to my saved trials
Assessment of Digital Breast Tomosynthesis (DBT) in the Screening Environment
Assessment of Digital Breast Tomosynthesis (DBT) in the Screening Environment: a Prospective Study
Status: Enrolling
Updated:  2/24/2016
Magee-Womens Hospital
mi
from
Pittsburgh, PA
Assessment of Digital Breast Tomosynthesis (DBT) in the Screening Environment
Assessment of Digital Breast Tomosynthesis (DBT) in the Screening Environment: a Prospective Study
Status: Enrolling
Updated: 2/24/2016
Magee-Womens Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Simple Versus Radical Hysterectomy for Stage I Cervical Cancer
Simple Versus Radical Hysterectomy for Stage I Cervical Cancer: Preferences of Women at High-Risk for Developing Cervix Cancer vs. Women Diagnosed With Cervix Cancer
Status: Enrolling
Updated:  2/25/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Simple Versus Radical Hysterectomy for Stage I Cervical Cancer
Simple Versus Radical Hysterectomy for Stage I Cervical Cancer: Preferences of Women at High-Risk for Developing Cervix Cancer vs. Women Diagnosed With Cervix Cancer
Status: Enrolling
Updated: 2/25/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Quit4Baby Evaluation
Developing and Scaling a Text Messaging Tool to Help Pregnant Smokers
Status: Enrolling
Updated:  2/25/2016
George Washington University
mi
from
Washington,
Quit4Baby Evaluation
Developing and Scaling a Text Messaging Tool to Help Pregnant Smokers
Status: Enrolling
Updated: 2/25/2016
George Washington University
mi
from
Washington,
Click here to add this to my saved trials
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  2/26/2016
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 2/26/2016
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  2/26/2016
Colorado Blood Cancer Institute
mi
from
Denver, CO
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 2/26/2016
Colorado Blood Cancer Institute
mi
from
Denver, CO
Click here to add this to my saved trials
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  2/26/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 2/26/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
PUFA Supplementation in Premature Infants
Early DHA Supplementation in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  2/26/2016
Prentice Women's Hospital
mi
from
Chicago, IL
PUFA Supplementation in Premature Infants
Early DHA Supplementation in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 2/26/2016
Prentice Women's Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
PUFA Supplementation in Premature Infants
Early DHA Supplementation in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  2/26/2016
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
PUFA Supplementation in Premature Infants
Early DHA Supplementation in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 2/26/2016
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
PUFA Supplementation in Premature Infants
Early DHA Supplementation in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  2/26/2016
NorthShore University HealthSystem
mi
from
Evanston, IL
PUFA Supplementation in Premature Infants
Early DHA Supplementation in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 2/26/2016
NorthShore University HealthSystem
mi
from
Evanston, IL
Click here to add this to my saved trials
Fetal Neurobehavior in Non-methadone Maintained Women in Substance Abuse Treatment
Fetal Neurobehavior in Non-methadone Maintained Women in Substance Abuse Treatment
Status: Enrolling
Updated:  2/29/2016
Johns Hopkins Bayview Medical Center
mi
from
Baltimore, MD
Fetal Neurobehavior in Non-methadone Maintained Women in Substance Abuse Treatment
Fetal Neurobehavior in Non-methadone Maintained Women in Substance Abuse Treatment
Status: Enrolling
Updated: 2/29/2016
Johns Hopkins Bayview Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Difference in Pain, Quality of Life Following Vaginal Hysterectomy With Vaginal Reconstruction Versus Robotic Colpopexy?
Is There a Difference in Pain and Quality of Life Following Vaginal Hysterectomy With Vaginal Reconstruction Compared to Robotic Colpopexy? A Prospective Cohort Study
Status: Enrolling
Updated:  2/29/2016
TriHealth Good Samaritan Hospital
mi
from
Cincinnati, OH
Difference in Pain, Quality of Life Following Vaginal Hysterectomy With Vaginal Reconstruction Versus Robotic Colpopexy?
Is There a Difference in Pain and Quality of Life Following Vaginal Hysterectomy With Vaginal Reconstruction Compared to Robotic Colpopexy? A Prospective Cohort Study
Status: Enrolling
Updated: 2/29/2016
TriHealth Good Samaritan Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate Cancer
Outcomes Following Intensity Modulated Radiation Therapy With And Without Erectile Tissue Dose Sparing For Favorable To Intermediate Risk Prostate Cancer
Status: Enrolling
Updated:  3/1/2016
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate Cancer
Outcomes Following Intensity Modulated Radiation Therapy With And Without Erectile Tissue Dose Sparing For Favorable To Intermediate Risk Prostate Cancer
Status: Enrolling
Updated: 3/1/2016
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate
Status: Enrolling
Updated:  3/1/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate
Status: Enrolling
Updated: 3/1/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Mobile, AL
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Phoenix, AZ
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Tucson, AZ
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Colton, CA
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Colton, CA
Click here to add this to my saved trials
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Los Angeles, CA
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials